ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis.

Víctor A Arrieta Johnny Duerinck Kirsten Bell Burdett Karl John Habashy Wietse Geens Andrew Gould Julia Katharina Schwarze Crismita Dmello Kwang-Soo Kim Ruth Saganty Li Chen Alberto Moscona Matthew McCord Catalina Lee-Chang Craig M Horbinski M-Marsel Mesulam Roger Stupp Bart Neyns Adam M Sonabend

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

This study strengthens the role of p-ERK as a predictive biomarker for OS in glioblastoma patients on immune checkpoint blockade. Future research should focus on further validation in prospective trials and the standardization of preanalytical variables influencing p-ERK quantification.

Keyphrases

signaling pathway
pi k akt
cell proliferation
end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
current status
patient reported outcomes
protein kinase
free survival